NICE guidance on pirfenidone for treating idiopathic pulmonary fibrosis.

The lancet. Respiratory medicine

Volumn 1, Issue 3, 2013, Pages 191-192

  Landells, Linda J ^a   Naidoo, Bhash ^a   Robertson, Janet ^a   Clark, Peter ^a  

^a NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PIRFENIDONE; PYRIDONE DERIVATIVE;

DISEASE COURSE; DRUG EFFECT; FIBROSING ALVEOLITIS; HUMAN; NATIONAL HEALTH SERVICE; NOTE; PATHOPHYSIOLOGY; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; UNITED KINGDOM; VITAL CAPACITY;

ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; GREAT BRITAIN; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; PRACTICE GUIDELINES AS TOPIC; PRODUCT SURVEILLANCE, POSTMARKETING; PYRIDONES; STATE MEDICINE; VITAL CAPACITY;

EID: 84893656489     PISSN: 22132600     EISSN: None     Source Type: None    
DOI: 10.1016/S2213-2600(13)70065-1     Document Type: Note

References (0)